Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of BAY 1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma

NCT04576091 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04576091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04576091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of BAY 1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 6, 2022
Completion date
January 14, 2027
Enrollment
7 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, clinical stage iv hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, recurrent head and neck cutaneous squamous cell carcinoma, recurrent head and neck squamous cell carcinoma, recurrent hypopharyngeal squamous cell carcinoma, recurrent laryngeal squamous cell carcinoma, recurrent oral cavity squamous cell carcinoma, recurrent oropharyngeal squamous cell carcinoma, recurrent paranasal sinus squamous cell carcinoma, recurrent salivary gland carcinoma, stage iii head and neck cutaneous squamous cell carcinoma ajcc v8, stage iii hypopharyngeal carcinoma ajcc v8, stage iii laryngeal cancer ajcc v8, stage iii lip and oral cavity cancer ajcc v8, stage iii major salivary gland cancer ajcc v8, stage iii oropharyngeal (p16-negative) carcinoma ajcc v8, stage iii sinonasal cancer ajcc v8, stage iv head and neck cutaneous squamous cell carcinoma ajcc v8, stage iv hypopharyngeal carcinoma ajcc v8, stage iv laryngeal cancer ajcc v8, stage iv lip and oral cavity cancer ajcc v8, stage iv major salivary gland cancer ajcc v8, stage iv oropharyngeal (p16-negative) carcinoma ajcc v8, stage iv sinonasal cancer ajcc v8, unresectable head and neck cutaneous squamous cell carcinoma, unresectable head and neck squamous cell carcinoma, unresectable hypopharyngeal squamous cell carcinoma, unresectable laryngeal squamous cell carcinoma, unresectable oral cavity squamous cell carcinoma, unresectable oropharyngeal squamous cell carcinoma, unresectable paranasal sinus squamous cell carcinoma, unresectable salivary gland squamous cell carcinoma